Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025929 | 1.00 | GRIN1 (0.32) | GRIN1GRIN2BKDM4EHTR2AHTR2C | |
| SCHEMBL3030992 | 0.95 | GRIN1 (0.31) | GRIN1GRIN2BKDM4EHTR2AHTR2C | |
| SCHEMBL3030990 | 0.95 | GRIN1 (0.31) | GRIN1GRIN2BKDM4EHTR2AHTR2C | |
| SCHEMBL3027946 | 0.90 | GRIN1 (0.33) | GRIN1GRIN2BKDM4ELMNAALDH1A1 | |
| SCHEMBL3027938 | 0.90 | GRIN1 (0.33) | GRIN1GRIN2BKDM4ELMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL3032341 | 0.89 | GRIN1 (0.33) | GRIN1GRIN2BKDM4ELMNAALDH1A1 | |
| SCHEMBL3027829 | 0.87 | RIPK1 (0.38) | KDM4ELMNA | |
| SCHEMBL3015251 | 0.84 | GRIN1 (0.33) | GRIN1GRIN2BKDM4ELMNA | |
| SCHEMBL3026547 | 0.84 | GRIN1 (0.33) | GRIN1GRIN2BKDM4ELMNA | |
| SCHEMBL3032363 | 0.80 | KDM4E (0.34) | GRIN1GRIN2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212309-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2212309-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-19 | — | — | EP | disclosed |
| US-8440701-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-14 | — | — | US | disclosed |
| US-8440701-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-14 | — | — | US | disclosed |
| US-8440701-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-14 | — | — | US | disclosed |
| US-20100216846-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216846-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216846-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-26 | — | — | US | disclosed |
| WO-2009050186-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216846-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNB1 | GRIN1 189/4885GRIN2B 225/4885KDM4E 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.